Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

358
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
358
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

211
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
211
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

2.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.8K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

1.3K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
1.3K
Carbohydrate Metabolism01:36

Carbohydrate Metabolism

11.2K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
11.2K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Development of a comprehensive real-world evidence dataset to inform diabetes policy: the diabetes data cell project.

BMC public health·2026
Same author

Simplified Switching to Once-Weekly Insulin Icodec Without an Initial One-Time Additional Dose Versus Once-Daily Insulin Glargine U100 in Basal Insulin-Treated Type 2 Diabetes (ONWARDS 10): A Randomised Controlled Trial.

Diabetes, obesity & metabolism·2026
Same author

Advancing Early-Stage Type 1 Diabetes Care: Future Focused Pathways for Identification, Screening, Diagnosis, and Monitoring.

Diabetes, obesity & metabolism·2026
Same author

GLP1-E2 therapy delays autoimmune diabetes in late-stage prediabetic NOD mice and potentiates low-dose anti-CD3 therapy for enhanced disease protection.

Diabetologia·2026
Same author

An international consensus on screening and monitoring early-stage type 1 diabetes: A roadmap to European implementation.

Diabetes, obesity & metabolism·2026
Same author

Mineralocorticoid receptor antagonists: Efficacy and safety in chronic kidney disease.

Diabetes, obesity & metabolism·2026

相关实验视频

Updated: Jul 19, 2025

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy
08:47

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy

Published on: December 7, 2017

9.8K

除了2型糖尿病之外的不变.

Chantal Mathieu1, Iraj Ahmadzai2

  • 1Department of Endocrinology, UZ Gasthuisberg, KU Leuven, Leuven, Belgium. chantal.mathieu@uzleuven.be.

Diabetologia
|August 8, 2023
PubMed
概括

在1型糖尿病中,添加到胰岛素治疗中的葡萄糖类-1 (GLP-1) 受体激活剂可以降低体重和胰岛素需求. 然而,对血糖控制和低血糖的影响因研究而异,胃肠道副作用很常见.

科学领域:

  • 内分泌学 在内分泌学.
  • 代谢疾病 代谢疾病
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 基于因克雷的疗法,特别是GLP-1受体激动剂,已被用于各种类型的糖尿病.
  • 随机对照试验 (RCT) 主要关注1型糖尿病患者.

研究的目的:

  • 审查1型糖尿病GLP-1受体激动剂的RCT中的证据.
  • 讨论临床影响和数据解释挑战.
  • 为了探索在其他形式的糖尿病中潜在的应用.

主要方法:

  • 随机对照试验的系统审查.
  • 分析有关体重,胰岛素剂量,血糖控制 (HbA1c) 和低血糖的数据.
  • 报告的副作用的评估.

主要成果:

  • 与安慰剂相比,GLP-1受体激活剂在1型糖尿病中添加到胰岛素治疗时,导致体重和胰岛素需求减少.
  • 对血糖控制 (HbA1c) 和低血糖风险的影响是可变的,这取决于具体的研究方案.
  • 常见的副作用包括胃肠道问题,如恶心,吐和腹.

结论:

关键词:
作为GLP-1受体的激动剂.葡萄糖控制 葡萄糖控制不同类型的隐形形象单一的糖尿病 单一的糖尿病审查 审查 审查 审查1 型糖尿病 1 型糖尿病重量 重量 重量 重量 重量

更多相关视频

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

94.5K
A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform
09:35

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform

Published on: July 16, 2016

11.2K

相关实验视频

Last Updated: Jul 19, 2025

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy
08:47

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy

Published on: December 7, 2017

9.8K
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

94.5K
A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform
09:35

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform

Published on: July 16, 2016

11.2K
  • GLP-1受体激动剂在强化胰岛素治疗的1型糖尿病患者的体重和胰岛素剂量降低方面显示出好处.
  • 控制葡萄糖的有效性取决于方案,需要仔细解释试验数据.
  • 目前对GLP-1受体激动剂在其他类型糖尿病中使用的证据有限.